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Current sensors employed in medicine are used to detect chemical and biochemical 
abnormalities. Their applications range from biopsy (brain), enzyme-linked immunosorbent 
assay (ELISA) (spinal fluid), blood (bio-barcode), and sweat and urine bio-diagnostics where the 
primary focus is the selection of biomarkers that can pinpoint the occurrence of the disease. 
Emerging sensors for cholesterol detection are based on enzymatic functions, which degrade 
these molecules, where the signal can be visualized optically by using a transducer. Cholesterol 
is a steroid metabolite that is employed for the synthesis of steroid hormones, and the 
establishment of proper membrane permeability and fluidity. Since cholesterol is insoluble in 
blood, it is transported in the circulatory system within lipoproteins, complex spherical particles 
which have an exterior comprising of amphiphilic proteins and lipids with outward-facing 
surfaces that are water-soluble and inward-facing surfaces that are lipid-soluble. Low-density 
lipoprotein (LDL) is known as ‘bad’ cholesterol. High-density lipoprotein (HDL) is known as 
‘good’ cholesterol. LDL is linked to cardiovascular conditions such as atherosclerosis and 
hypertension, which ultimately lead to coronary heart disease, myocardial and cerebral 
infarction (stroke). An appropriate therapeutic response to a sensor system for cholesterol, 
specifically LDL, detection implicates the design of an implantable system for stimuli-responsive 
drug release. The proposed system was designed to detect specific biochemical changes by 
employing nanoparticles made of glyceryl behenate, polyoxyethylene-polyoxypropylene block 
copolymer, avidin, biotin and anti-beta lipoprotein antibodies as sensors. This was achieved by 
coating nanoparticles with antibodies specific to the antigen (i.e. LDL) to create an antibody-
conjugated antibody conjugated solid lipid nanoparticles (henceforth known as ‘antibody 
conjugated SLN). Fenofibrate was used as a model drug due to its low water solubility and to its 
lipophilic properties similar to statins. The antibody conjugated SLNs were of 150nm in size and 
had a zeta potential of -28mV. Their drug entrapment efficacy was 86%, with a drug release of 
16mg/day due to Fickian diffusion and erosion mechanism. The slow release was due semi-
crystalline structure determined by XRD and DSC. Antigen responsive hydrogel was designed 
by incorporation of thiolated antibody conjugated SLN via Traut’s reagents, polyethylene glycol 
diacrylate, methyl acrylic acid and polyethylene glycol 200. The osmotic pump was designed 
from polyethylene oxide, ethyl cellulose and mannitol. The drug reservoir was synthesized from 
ethyl cellulose coated gelatin capsule via coacervation phase separation method. The polymeric 
tube synthesized from ethyl cellulose, methyl cellulose and castor oil was coated with antigen 
responsive hydrogel. Ex vivo studies evaluating intravascular stability of the implant in 
correlation with mechanical analysis indicated the polymeric tube unstable. An 18-gauge 
catheter was used for forming an infusion tube as a substitute for the polymeric tube. The 
implant showed a correlation of Korsmeyer-Peppas drug release during in vivo and in vitro 
studies. A constant drug release of 881µg/day was observed during in vivo. This played a role in 
reduction of total cholesterol by means of reduction in LDL sub-fractions by 30%; in correlation 
with LDL particle enhance clearance from the plasma due to SLN-LDL uptake. An increase by 
46% in HDL was observed, which correlated to fenofibrate therapeutic effect. Pharmacokinetic 
analysis indicated improved mean residence time and efficacy. This indicated that the device 
could be used for delivery of lipophilic drugs and detection of circulating biomarkers. 
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